Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rucaparib + Nivolumab in Ovarian Cancer (ARIES)
NCT03824704Phase 2Terminated
- Sponsor
- pharma&
- Start
- Aug 2019
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rucaparib in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by pharma&. Started Aug 2019; status: terminated.
02
Drugs
rucaparib
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT03824704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03824704.